公开(公告)号：WO2023064519A1

公开(公告)日：2023-04-20

申请号：PCT/US2022/046645

申请日：2022-10-14

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： KORDIC, Lorena ,  TRAVANCIC, Valentina ,  LANDEKA, Ivana ,  JANTON, Nikolina

IPC分类号： C07C217/84 ,  C07C275/02 ,  A61K31/137 ,  A61K31/17 ,  A61P35/00

摘要： The present invention concerns a co-crystal of Elacestrant dihydrochloride and urea, its use in the preparation of another solid state form of Elecestrant or a salt thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2022261401A1

公开(公告)日：2022-12-15

申请号：PCT/US2022/032952

申请日：2022-06-10

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： KARADAKIĆ, Klara ,  LANDEKA, Ivana ,  TRAVANČIĆ, Valentina ,  ŠKALEC ŠAMEC, Dijana

IPC分类号： A61P35/00 ,  C07C303/32 ,  C07D311/66 ,  A61K31/343 ,  C07C55/02

摘要： Solid state forms of Abexinostat salts and of Abexinostat tosylate : p-toluenesulfonic acid monohydrate complex, processes for preparation thereof, pharmaceutical compositions and uses thereof are disclosed.

公开(公告)号：WO2022225712A1

公开(公告)日：2022-10-27

申请号：PCT/US2022/023758

申请日：2022-04-07

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： LAPIDO, Polina ,  RUDIK, Doron

IPC分类号： C07C323/66 ,  A61P9/12

摘要： The present disclosure encompasses solid state forms of Firibastat and salts or co-crystals thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2022197884A1

公开(公告)日：2022-09-22

申请号：PCT/US2022/020684

申请日：2022-03-17

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： LAPIDO, Polina ,  SHUMACHER, Inbal ,  SHAUL, Ofir ,  RUDIK, Doron ,  ROMANOVA, Jana ,  KOLESA, Pavel

IPC分类号： C07D403/04 ,  C07D413/14 ,  A61K31/53 ,  A61P35/00

摘要： The present disclosure encompasses solid state forms of Zandelisib and HCI or HBr salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2022020279A1

公开(公告)日：2022-01-27

申请号：PCT/US2021/042266

申请日：2021-07-20

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： MUTHUSAMY, Anantha Rajmohan ,  SINGH, Amit ,  PUTIKUM, Rahul Kumar Reddy

IPC分类号： C07D471/04 ,  A61P35/00 ,  A61K31/437 ,  A61K31/4995

摘要： The present disclosure encompasses solid state forms of Selpercatinib, in embodiments crystalline polymorphs of Selpercatinib, processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2021236709A1

公开(公告)日：2021-11-25

申请号：PCT/US2021/033060

申请日：2021-05-19

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： LAPIDO, Polina ,  RUDIK, Doron

IPC分类号： C07C39/21 ,  A61P17/06 ,  A61P17/00

摘要： The present disclosure encompasses solid state forms of Tapinarof, in embodiments crystalline polymorphs or co-crystals of Tapinarof, processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2021046014A1

公开(公告)日：2021-03-11

申请号：PCT/US2020/048878

申请日：2020-09-01

申请人： TEVA CZECH INDUSTRIES S.R.O ,  TEVA PHARMACEUTICALS USA, INC.

发明人： TRČKOVÁ, Zuzana ,  BÁRTOVÁ, Adéla ,  KOLESA, Pavel ,  JEGOROV, Alexandr

IPC分类号： C07D487/22 ,  A61P35/00 ,  A61K31/55

摘要： The present disclosure encompasses solid state forms of Pamiparib, including crystalline polymorphs of Pamiparib, co-crystals and salts of Pamiparib, as well as processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2021026307A1

公开(公告)日：2021-02-11

申请号：PCT/US2020/045128

申请日：2020-08-06

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： LUTHRA, Parven Kumar ,  AHMAD, Suhail ,  KISHOR, Neval ,  GOSWAMI, Miteshgir Kanchangir ,  SINGH, Alok ,  SINHA, Chandrasekhar ,  QUADRI, Syed Aziz Imam ,  JOSHI, Prashant Shankar ,  MAURYA, Sadanand Hardeo

IPC分类号： C07D217/26

摘要： The present invention provides new procedure and intermediates for the preparation of Roxadustat (1) comprising: (A) reducing a compound of formula 3', 3" or a mixture thereof: (3'), (3") wherein Pg is H or a OH protecting group, Ri is alkyl, aryl, or arylalkyl; R 2 , R 3 , R 4 , and Rs each independently represents alkyl, arylalkyl or alkenyl, or R 2 and R 3 and/or R 4 and Rs, taken together with the nitrogen atom to which they are bonded, each independently form a ring selected from: (I), wherein R 6 is H or C I- 6 alkyl; R 7 is Ci to C6 alkyl and X- is an anion selected from the group consisting of halide, O-SO 4 -R 7 wherein R 7 is Ci to C 6 alkyl, or O-SO 2 -Rs wherein Rs is phenyl, tolyl, methyl or trifluoromethyl; to form a compound of formula (2') wherein Pg is H or an OH protecting group, Ri is alkyl, aryl, or arylalkyl; and removing the Ri group and where present removing the OH protecting group; or (B) reducing a compound of formula 4', a compound of formula 4" or a mixture thereof: (4'), (4") wherein Pg is H or an OH protecting group; Ri is H, alkyl, aryl, or arylalkyl; R 2 , R 3 , R 4 , and R5 each independently represents alkyl, aryl, arylalkyl or alkenyl; or R 2 is Ci- 4 alkyl and R 3 is Ci- 4 alkoxy; or R 2 and R 3 and/or R 4 and R 5 , taken together with the nitrogen atom to which they are bonded, each independently form a group selected from: (I) wherein R 6 is H or C I-6 alkyl; and where Ri is not H, removing the Ri group, and, where present removing the OH protecting group.

公开(公告)号：WO2021021775A1

公开(公告)日：2021-02-04

申请号：PCT/US2020/043815

申请日：2020-07-28

申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH ,  TEVA PHARMACEUTICALS USA, INC.

发明人： MATEČIĆ MUŠANIĆ, Sanja ,  KLARIC, Dario ,  KOLENIC, Mateja

IPC分类号： C07D519/00 ,  A61P21/00 ,  A61P25/00

摘要： The present disclosure encompasses solid state forms of Risdiplam, including crystalline polymorphs of Risdiplam, processes for preparation thereof, and pharmaceutical compositions thereof.

公开(公告)号：WO2021011345A1

公开(公告)日：2021-01-21

申请号：PCT/US2020/041524

申请日：2020-07-10

申请人： PLIVA HRVATSKA D.O.O ,  TEVA PHARMACEUTICALS USA, INC.

发明人： KORDIC, Lorena ,  GREBENAR, Ivica ,  ŠAMEC, Dijana Škalec

IPC分类号： C07D498/18 ,  A61P35/00

摘要： The present disclosure relates to crystalline Lorlatinib : Fumaric acid, solid state forms thereof, processes for preparation thereof, pharmaceutical compositions and methods of use thereof.